PAX3 and metastatic neoplasm: Interestingly, while fusion subtype does not affect survival of patients presenting without clinically overt distal metastases, patients presenting with PAX3/FOXO1 metastatic disease appear to have worse outcomes than those with PAX7/FOXO1 metastatic disease [6].